{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:58Z","timestamp":1792788598388,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The Leuka Charity"},{"name":"National Measurment System"},{"name":"UK National Measurement System"},{"name":"UK National Measurement Office"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the percentage of the fusion transcript BCR-ABL1 (breakpoint cluster region\u2013c-abl oncogene 1, non-receptor tyrosine kinase) BCR-ABL1IS (%BCR-ABL1IS) by reverse transcription\u2013quantitative PCR (RT-qPCR) is the gold standard strategy for evaluating patient response to TKIs and classification into prognostic subgroups. However, this approach can be challenging to perform in a reproducible manner. Reverse-transcription digital PCR (RT-dPCR) is an adaptation of this method that could provide the robust and standardized workflow needed for truly standardized patient stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>BCR-ABL1 and ABL1 transcript copy numbers were quantified in a total of 102 samples; 70 CML patients undergoing TKI therapy and 32 non-CML individuals. 3 commercially available digital PCR platforms (QS3D, QX200 and Raindrop) were compared with the platform routinely used in the clinic for RT-qPCR using the EAC (Europe Against Cancer) assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Measurements on all instruments correlated well when the %BCR-ABL1IS was \u22650.1%. In patients with residual disease below this level, greater variations were measured both within and between instruments limiting comparable performance to a 4 log dynamic range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>RT-dPCR was able to quantify low-level BCR-ABL1 transcript copies but was unable to improve sensitivity below the level of detection achieved by RT-qPCR. However, RT-dPCR was able to perform these sensitive measurements without use of a calibration curve. Adaptions to the protocol to increase the amount of RNA measured are likely to be necessary to improve the analytical sensitivity of BCR-ABL testing on a dPCR platform.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1373\/clinchem.2016.262824","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T21:50:42Z","timestamp":1481838642000},"page":"525-531","source":"Crossref","is-referenced-by-count":67,"title":["RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia"],"prefix":"10.1093","volume":"63","author":[{"given":"Mary","family":"Alikian","sequence":"first","affiliation":[{"name":"Imperial Molecular Pathology, Imperial Healthcare Trust, Hammersmith Hospital, London, UK"},{"name":"Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra S","family":"Whale","sequence":"first","affiliation":[{"name":"Molecular and Cell Biology Team, LGC, Queens Road, Teddington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Akiki","sequence":"first","affiliation":[{"name":"West Midlands Regional Genetics Laboratories, Birmingham Women's NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Piechocki","sequence":"first","affiliation":[{"name":"West Midlands Regional Genetics Laboratories, Birmingham Women's NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Torrado","sequence":"first","affiliation":[{"name":"Imperial Molecular Pathology, Imperial Healthcare Trust, Hammersmith Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thet","family":"Myint","sequence":"first","affiliation":[{"name":"Imperial Molecular Pathology, Imperial Healthcare Trust, Hammersmith Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cowen","sequence":"first","affiliation":[{"name":"Statistics Team, LGC, Queens Road, Teddington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Griffiths","sequence":"first","affiliation":[{"name":"West Midlands Regional Genetics Laboratories, Birmingham Women's NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair G","family":"Reid","sequence":"first","affiliation":[{"name":"Imperial Molecular Pathology, Imperial Healthcare Trust, Hammersmith Hospital, London, UK"},{"name":"Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Apperley","sequence":"first","affiliation":[{"name":"Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"White","sequence":"first","affiliation":[{"name":"National Genetics Reference Laboratory (Wessex), Salisbury District Hospital, Salisbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim F","family":"Huggett","sequence":"first","affiliation":[{"name":"Molecular and Cell Biology Team, LGC, Queens Road, Teddington, UK"},{"name":"School of Biosciences & Medicine, Faculty of Health & Medical Science, University of Surrey, Guildford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Foroni","sequence":"first","affiliation":[{"name":"Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK"},{"name":"Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"2020022606071138000_B1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"2020022606071138000_B2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020022606071138000_B3","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J Clin Oncol"},{"key":"2020022606071138000_B4","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"2020022606071138000_B5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.V120.21.1675.1675","article-title":"Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data","volume":"120","author":"Saglio","year":"2012","journal-title":"Blood"},{"key":"2020022606071138000_B6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"2020022606071138000_B7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"2020022606071138000_B8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"2020022606071138000_B9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2020022606071138000_B10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","article-title":"Considerations for digital PCR as an accurate molecular diagnostic tool","volume":"61","author":"Huggett","year":"2015","journal-title":"Clin Chem"},{"key":"2020022606071138000_B11","doi-asserted-by":"crossref","first-page":"e75296","DOI":"10.1371\/journal.pone.0075296","article-title":"Evaluation of digital PCR for absolute RNA quantification","volume":"8","author":"Sanders","year":"2013","journal-title":"PLoS One"},{"key":"2020022606071138000_B12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/leu.2014.217","article-title":"A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR","volume":"29","author":"White","year":"2015","journal-title":"Leukemia"},{"key":"2020022606071138000_B13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1373\/clinchem.2013.206375","article-title":"The Digital MIQE Guidelines: minimum information for publication of quantitative digital PCR experiments","volume":"59","author":"Huggett","year":"2013","journal-title":"Clin Chem"},{"key":"2020022606071138000_B14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE Guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin Chem"},{"key":"2020022606071138000_B15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21457","article-title":"Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia","volume":"84","author":"Foroni","year":"2009","journal-title":"Am J Hematol"},{"key":"2020022606071138000_B16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br J Haematol"},{"key":"2020022606071138000_B17","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"2020022606071138000_B18","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"2020022606071138000_B19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ajh.23212","article-title":"Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization","volume":"87","author":"Gerrard","year":"2012","journal-title":"Am J Hematol"},{"key":"2020022606071138000_B20","doi-asserted-by":"crossref","first-page":"17807","DOI":"10.1073\/pnas.0608512103","article-title":"Transcription factor profiling in individual hematopoietic progenitors by digital RT-PCR","volume":"103","author":"Warren","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020022606071138000_B21","article-title":"The Digital Array Response Curve","author":"Warren","journal-title":"Department of Bioengineering"},{"key":"2020022606071138000_B22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymeth.2010.01.003","article-title":"Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution","volume":"50","author":"Weaver","year":"2010","journal-title":"Methods"},{"key":"2020022606071138000_B23","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1021\/ac103230c","article-title":"Evaluation of digital PCR for absolute DNA quantification","volume":"83","author":"Sanders","year":"2011","journal-title":"Anal Chem"},{"key":"2020022606071138000_B24","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1093\/nar\/gks203","article-title":"Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation","volume":"40","author":"Whale","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2020022606071138000_B25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat Methods"},{"key":"2020022606071138000_B26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2164-10-116","article-title":"Digital PCR provides sensitive and absolute calibration for high throughput sequencing","volume":"10","author":"White","year":"2009","journal-title":"BMC genomics"},{"key":"2020022606071138000_B27","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00216-009-3200-3","article-title":"Absolute quantification of genetically modified MON810 maize (Zea mays L.) by digital polymerase chain reaction","volume":"396","author":"Corbisier","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"2020022606071138000_B28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jmoldx.2012.09.007","article-title":"Standard reference material 2366 for measurement of human cytomegalovirus DNA","volume":"15","author":"Haynes","year":"2013","journal-title":"J Mol Diagn"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/63\/2\/525\/32646187\/clinchem0525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/63\/2\/525\/32646187\/clinchem0525.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T06:18:51Z","timestamp":1582697931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/63\/2\/525\/5612870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,1]]},"published-print":{"date-parts":[[2017,2,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2016.262824","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,2,1]]},"published":{"date-parts":[[2017,2,1]]}}}